J Am Acad Dermatol by Fu, Teresa et al.
Characterizing subsequent primary melanomas in adolescents 
and young adults: a population-based study from 1973-2011
Teresa Fu, MD1, Susan M. Swetter, MD1,2, Li Tao, PhD, MD, MS3, Alan C. Geller, MPH, RN4, 
Christina A. Clarke, PhD, MPH3,5, and Theresa H.M. Keegan, PhD, MS3,6
1Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University 
Medical Center and Cancer Institute, Stanford, CA
2Dermatology Service, VA Palo Alto Health Care System, Palo Alto, CA
3Cancer Prevention Institute of California, Fremont, CA
4Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA
5Division of Epidemiology, Department of Health Research and Policy, Stanford University School 
of Medicine, Stanford, CA
6Division of Hematology and Oncology, Department of Internal Medicine, University of California 
Davis School of Medicine, Sacramento, CA
To the Editor
Melanoma is among the most common cancers diagnosed in adolescents and young adults 
(AYAs). Recent studies show an increasing incidence in young women and a worse 
prognosis in young men1,2. Prior studies have shown that a first diagnosis of melanoma 
elevates second malignancy risk, especially for melanoma3. We sought to characterize a 
population of male and female AYAs diagnosed with 2 or more primary melanomas 
between the ages of 15 and 39 4. Study of patients who develop multiple melanomas at a 
young age may help elucidate genetic and environmental factors that increase melanoma 
risk.
Methods
We used the Surveillance, Epidemiology and End Results (SEER) 18 cancer registry 
database (1973-2011), which has incorporated additional cancer registries to maximize 
sample size. We obtained patient demographic and clinical data on 551 AYAs with an 
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invasive first primary melanoma (FPM) and subsequent primary melanoma (SPM) and 
38,110 AYAs with only FPM5. Multivariable logistic regression was used to examine 
characteristics associated with developing a SPM.
Results
Most (67.7%) SPM developed within 5 years of FPM diagnosis and in females (65.3%). 
Females had more SPM on the extremities and were more likely to develop SPM at a 
different anatomical site (p=0.03). Males developed more SPM on the trunk and head/neck 
and were more likely to have an ulcerated SPM and/or present with regional or metastatic 
SPM (10.5% vs. 5.2%) (p=0.03) (Table 1). There was a trend towards thicker tumors in 
males for both FPM and SPM. In the multivariable comparison to AYAs with only one 
melanoma, non-Hispanic white race/ethnicity, younger age at FPM diagnosis, and female 
gender were associated with higher odds of SPM (Table 2).
Discussion
Prior studies show an increased risk for SPM in AYAs diagnosed with melanoma compared 
to middle-aged melanoma patients, and this increase is not merely a reflection of longer 
follow-up6. We found AYA females were more likely to develop a SPM, but males were 
more likely to present with advanced SPM. Biologic sex differences in host immunity or 
tumor factors could partially explain the latter finding, as evidenced by a prior study 
demonstrating a poorer prognosis in male AYAs with melanoma compared with females1.
The association between SPM and younger age of FPM may relate to genetic predisposition 
or increased UV exposure at a younger age and tanning practices, particularly in women. 
The higher odds of SPM in those with ulcerated FPM was more commonly observed in men 
and may stem from the trend for thicker tumors in males, underlying genetic predisposition, 
or suboptimal screening access that could lead to more advanced presentation of FPM, while 
also contributing to increased risk for SPM.
Education regarding risk of new skin cancers and appropriate screening are especially 
important for AYAs, among whom the risk for SPM remains elevated for many years3,6. 
Determining whether AYAs who develop multiple melanomas before age 40 have 
associated germ-line mutations is an important area of future study.
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Table 1
Demographic and clinical characteristics of adolescents and young adults (AYAs) 










Age at diagnosis for the 1st
melanoma 0.21
  15-24 115 20.9% 33 17.3% 82 22.8%
  25-29 143 26.0% 45 23.6% 98 27.2%
  30-34 189 34.3% 74 38.7% 115 31.9%
  35-39 104 18.9% 39 20.4% 65 18.1%
Age at diagnosis for the 2nd
melanoma 0.08
  15-24 45 8.2% 16 8.4% 29 8.1%
  25-29 107 19.4% 27 14.1% 80 22.2%
  30-34 144 26.1% 48 25.1% 96 26.7%
  35-39 255 46.3% 100 52.4% 155 43.1%
Race/ethnicity 0.53
  Non-Hispanic white 542 98.4% 187 97.9% 355 98.6%
  Other*/unknown 9 1.6% <5 2.1% 5 1.4%
Year of diagnosis for the 1st
melanoma 0.48
  1973-1983 54 9.8% 16 8.4% 38 10.6%
  1984-1993 90 16.3% 35 18.3% 55 15.3%
  1994-2003 203 36.8% 75 39.3% 128 35.6%
  2004-2011 204 37.0% 65 34.0% 139 38.6%
Year of diagnosis for the 2nd
melanoma 0.22
  1973-1983 27 4.9% 7 3.7% 20 5.6%
  1984-1993 69 12.5% 31 16.2% 38 10.6%
  1994-2003 146 26.5% 48 25.1% 98 27.2%
  2004-2011 309 56.1% 105 55.0% 204 56.7%
Time intervals between the
1st and 2nd melanoma 0.57
  Under 3 months 36 6.5% 10 5.2% 26 7.2%
  4-11 months 35 6.4% 9 4.7% 26 7.2%
  Diagnosed within the same
  year, but interval unknown <5 0.7% <5 0.5% <5 0.8%
  1 year 145 26.3% 50 26.2% 95 26.4%
  2-5 years 217 39.4% 85 44.5% 132 36.7%
  6-10 years 92 16.7% 30 15.7% 62 17.2%
  11+ years 22 4.0% 6 3.1% 16 4.4%
Anatomical site for the 1st
melanoma <0.001
  Head and neck 65 11.8% 39 20.4% 26 7.2%






















  Trunk 237 43.0% 93 48.7% 144 40.0%
  Upper extremity 100 18.1% 29 15.2% 71 19.7%
  Lower extremity 138 25.0% 26 13.6% 112 31.1%
  Others/Unknown 11 2.0% <5 2.1% 7 1.9%
Anatomical site for the 2nd
melanoma <0.001
  Head and neck 70 12.7% 43 22.5% 27 7.5%
  Trunk 231 41.9% 87 45.5% 144 40.0%
  Upper extremity 104 18.9% 30 15.7% 74 20.6%
  Lower extremity 138 25.0% 29 15.2% 109 30.3%
  Other or unknown 8 1.5% <5 1.0% 6 1.7%
Anatomical site same for the
2nd melanoma 0.03
  Yes 220 39.9% 88 46.1% 132 36.7%
  No 331 60.1% 103 53.9% 228 63.3%
Histopathologic subtype for
the 1st melanoma 0.16
  Superficial spreading 257 46.6% 84 44.0% 173 48.1%
  Nodular 28 5.1% 15 7.9% 13 3.6%
  Rare subtypes 25 4.5% 10 5.2% 15 4.2%
  Not otherwise specified 241 43.7% 82 42.9% 159 44.2%
Histopathologic subtype for
the 2nd melanoma 0.04
  Superficial spreading 243 44.1% 75 39.3% 168 46.7%
  Nodular 18 3.3% 11 5.8% 7 1.9%
  Rare subtypes 25 4.5% 7 3.7% 18 5.0%
  Not otherwise specified 265 48.1% 98 51.3% 167 46.4%
Tumor extension 1st mm 0.12
  Cutaneous disease 490 88.9% 162 84.8% 328 91.1%
  Regional disease 43 7.8% 22 11.5% 21 5.8%
  Metastatic disease <5 0.5% <5 0.5% <5 0.6%
  Unknown 15 2.7% 6 3.1% 9 2.5%
Tumor extension 2nd mm 0.03
  Cutaneous disease 486 88.2% 160 83.8% 326 90.6%
  Regional disease 29 5.3% 17 8.9% 12 3.3%
  Metastatic disease 10 1.8% <5 1.6% 7 1.9%
  Unknown 26 4.7% 11 5.8% 15 4.2%
Tumor thickness (1988
forward*), mm for 1st
melanoma 0.01±
  0.01-1.00 340 73.0% 105 65.2% 235 77.0%
  1.01-2.00 52 11.2% 21 13.0% 31 10.2%
  2.01-4.00 29 6.2% 18 11.2% 11 3.6%
  >4.01 7 1.5% <5 2.5% <5 1.0%






















  Unknown 38 8.2% 13 8.1% 25 8.2%
Tumor thickness (1988
forward**), mm for 2nd
melanoma 0.01±
  0.01-1.00 358 76.8% 111 68.9% 247 81.0%
  1.01-2.00 27 5.8% 17 10.6% 10 3.3%
  2.01-4.00 12 2.6% 6 3.7% 6 2.0%
  >4.01 9 1.9% 5 3.1% <5 1.3%
  Unknown 60 12.9% 22 13.7% 38 12.5%
Ulcerated (2004 forward**) 1st
melanoma 0.10±
  No 173 84.8% 50 76.9% 123 88.5%
  Yes 21 10.3% 10 15.4% 11 7.9%
  Unknown 10 4.9% 5 7.7% 5 3.6%
Ulcerated (2004 forward#) 2nd
melanoma <0.01±
  No 182 89.2% 56 86.2% 126 90.6%
  Yes 7 3.4% 5 7.7% <5 1.4%
  Unknown 15 7.4% <5 6.2% 11 7.9%
*
Other race/ethnicity includes blacks, Asian/Pacific Islanders and American Indian/Alaskan Natives.
**
Tumor thickness data is only available for cases diagnosed after 1988; Information on depth for cases diagnosed before 1988 may be available in 
different versions of coding but are complicated to incorporate.
#
Ulceration information is available for cases diagnosed after 2004 only.
±
p for difference from chi-square test excludes patients before 1988 for tumor thickness and patients before 2004 for ulceration.
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Table 2
Demographic and clinical factors associated with subsequent primary melanoma (SPM) 
(versus only a first primary melanoma (FPM)) in Adolescents and Young Adults (AYAs): 









Year of diagnosis for the
1st (or only) melanoma <0.01
  1973-1983 4205 11.0% 54 9.8% Reference
  1984-1993 6508 17.1% 90 16.3% 1.14 (0.81-1.61)
  1994-2003 12830 33.7% 203 36.8% 1.34 (0.99-1.81)
  2004-2011 14567 38.2% 204 37.0% 1.19 (0.88-1.61)
Age at diagnosis for the
1st (or only) melanoma
(years) <0.01
  15-24 5971 15.7% 115 20.9% Reference
  25-29 7755 20.3% 143 26.0% 0.96 (0.75-1.23)
  30-34 10617 27.9% 189 34.3% 0.93 (0.73-1.17)
  35-39 13767 36.1% 104 18.9% 0.39 (0.30-0.51)
Race <0.01
  Non-Hispanic white 35322 92.7% 542 98.4% Reference
  Other#/unknown 2788 7.3% 9 1.6% 0.20 (0.10-0.39)
Sex 0.01
  Male 15267 40.1% 191 34.7% Reference
  Female 22843 59.9% 360 65.3% 1.21 (1.01-1.45)
Anatomical site for the 1st
(or only) melanoma 0.08
  Head and neck 4419 11.6% 65 11.8% Reference
  Trunk 15000 39.4% 237 43.0% 1.07 (0.81-1.42)
  Upper extremity 7885 20.7% 100 18.1% 0.87 (0.63-1.20)
  Lower extremity 9347 24.5% 138 25.0% 0.98 (0.72-1.32)
  Other/unknown 1459 3.8% 11 2.0% 0.56 (0.29-1.07)
Histopathologic subtype
for the 1st (or only)
melanoma 0.25
  Superficial spreading 16215 42.5% 257 46.6% Reference
  Nodular 2212 5.8% 28 5.1% 0.80 (0.54-1.19)
  Rare subtypes 1664 4.4% 25 4.5% 1.03 (0.68-1.56)
  Not otherwise
  specified 18019 47.3% 241 43.7% 0.86 (0.72-1.03)
Tumor thickness (1988
forward ±), mm for the 1st
(or only) melanoma 0.04
  0.01-1.00 21464 68.1% 340 73.0% Reference
  1.01-2.00 3834 12.2% 52 11.2% 0.86 (0.64-1.15)
  2.01-4.00 1672 5.3% 29 6.2% 1.12 (0.75-1.68)






















  >4.01 810 2.6% 7 1.5% 0.60 (0.28-1.30)
  Unknown 3757 11.9% 38 8.2% 0.69 (0.49-0.98)
Ulcerated (2004 forward ∞)
1st (or only) melanoma 0.08
  No 12319 84.6% 173 84.8% Reference
  Yes 1061 7.3% 21 10.3% 1.65 (0.99-2.76)
  Unknown 1187 8.1% 10 4.9% 0.97 (0.48-1.97)
*
Odds ratios adjusted for all variables in the table.
**
p for difference from chi-square test excludes patients before 1988 for tumor thickness and patients before 2004 for ulceration.
#
Other race/ethnicity includes blacks, Asian/Pacific Islanders and American Indian/Alaskan Natives.
±
Tumor thickness data is only available for cases diagnosed after 1988.
∞
Ulceration information is only available for cases diagnosed after 2004.
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